Efficacy and safety of eltrombopag in the treatment of immune thrombocytopenia patients with hepatitis B virus infection: A prospective, multicenter, single arm, phase <scp>II</scp> trial-Reference-Cited by-同舟云学术

Efficacy and safety of eltrombopag in the treatment of immune thrombocytopenia patients with hepatitis B virus infection: A prospective, multicenter, single arm, phase II trial

Published:2023-10-26 Issue:1 Volume:99 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Chen Yunfei¹²^ORCID,Xu Yanmei¹²^ORCID,Huang Yueting³^ORCID,Sun Ting¹²^ORCID,Hu Yuefen⁴^ORCID,Xue Feng¹²^ORCID,Peng Xuanwei⁵,Lai Yinghui⁵,Zhou Zeping⁶,Zhou Hu⁷,Zhou Rongfu⁸,Liu Wei¹²,Liu Xiaofan¹²^ORCID,Dong Huan¹²^ORCID,Fu Rongfeng¹²,Ju Mankai¹²,Dai Xinyue¹²,Li Huiyuan¹²,Liu Xiaonan¹²,Ma Yueshen¹²,Song Zhen¹²,Peng Jun⁴^ORCID,Yang Renchi¹²^ORCID,Zhang Lei¹²^ORCID

Affiliation:

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases Tianjin China

2. Tianjin Institutes of Health Science Tianjin China

3. Department of Hematology The First Affiliated Hospital of Xiamen University Xiamen Fujian China

4. Department of Hematology, Qilu Hospital Shandong University Jinan China

5. The Second Affiliated Hospital of Guangxi Medical University Nanning China

6. The Second Affiliated Hospital of Kunming Medical University Kunming China

7. Henan Cancer Hospital Zhengzhou China

8. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Nanjing China

Funder

Chinese Academy of Medical Sciences Initiative for Innovative Medicine

National Natural Science Foundation of China

Publisher

Wiley